Finance

Sciele Pharma raises 2006 revenue guidance to $290-292 million, reaffirms 2007 guidance

Published in Blood Weekly, February 8th, 2007

Patrick Fourteau, president and chief executive officer of Sciele Pharma, Inc. (SCRX), raised the company's revenue guidance for full-year 2006 to between $290 million and $292 million from the previously announced range of $287 million to $290 million and raised the earnings guidance to between $1.18 and $1.20 per share from the previously announced range of $1.16 to $1.19 per share.

Fourteau, speaking at the JPMorgan Healthcare Conference in San Francisco, California, also reaffirmed the company's previously announced full-year 2007 revenue guidance of $335 million to $350 million and diluted earnings per share guidance of $1.53 to $1.62.

Fourteau...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2007-02-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry